B. Metzler seel. Sohn & Co. AG reduced its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 45.0% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 18,305 shares of the biopharmaceutical company's stock after selling 14,986 shares during the period. B. Metzler seel. Sohn & Co. AG's holdings in Intra-Cellular Therapies were worth $1,529,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds also recently made changes to their positions in ITCI. China Universal Asset Management Co. Ltd. increased its position in Intra-Cellular Therapies by 10.6% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 22,480 shares of the biopharmaceutical company's stock worth $1,878,000 after purchasing an additional 2,157 shares during the period. Barclays PLC grew its position in shares of Intra-Cellular Therapies by 282.0% during the 3rd quarter. Barclays PLC now owns 34,453 shares of the biopharmaceutical company's stock worth $2,521,000 after buying an additional 25,435 shares during the period. Oak Ridge Investments LLC raised its stake in shares of Intra-Cellular Therapies by 74.1% during the fourth quarter. Oak Ridge Investments LLC now owns 19,831 shares of the biopharmaceutical company's stock worth $1,656,000 after buying an additional 8,440 shares during the last quarter. Principal Financial Group Inc. boosted its stake in Intra-Cellular Therapies by 3.3% in the third quarter. Principal Financial Group Inc. now owns 597,713 shares of the biopharmaceutical company's stock valued at $43,735,000 after acquiring an additional 18,865 shares during the last quarter. Finally, Merit Financial Group LLC bought a new position in Intra-Cellular Therapies in the fourth quarter valued at approximately $206,000. Institutional investors own 92.33% of the company's stock.
Intra-Cellular Therapies Stock Performance
Shares of ITCI remained flat at $131.87 during midday trading on Monday. The firm has a market capitalization of $14.05 billion, a P/E ratio of -151.57 and a beta of 0.69. The stock has a fifty day simple moving average of $129.62 and a 200-day simple moving average of $101.80. Intra-Cellular Therapies, Inc. has a 12-month low of $64.09 and a 12-month high of $131.98.
Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last announced its earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. The firm had revenue of $199.22 million during the quarter, compared to analyst estimates of $205.08 million. Equities analysts expect that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current fiscal year.
Analysts Set New Price Targets
A number of research analysts have recently weighed in on ITCI shares. Cantor Fitzgerald reissued a "neutral" rating and issued a $132.00 price target on shares of Intra-Cellular Therapies in a research note on Wednesday, April 2nd. Mizuho lowered Intra-Cellular Therapies from an "outperform" rating to a "neutral" rating and cut their target price for the company from $140.00 to $132.00 in a research note on Monday, February 24th. Leerink Partnrs lowered Intra-Cellular Therapies from a "strong-buy" rating to a "hold" rating in a research report on Monday, January 13th. Royal Bank of Canada reiterated a "sector perform" rating and issued a $132.00 price target (up from $108.00) on shares of Intra-Cellular Therapies in a research report on Wednesday, January 22nd. Finally, StockNews.com assumed coverage on shares of Intra-Cellular Therapies in a report on Saturday. They set a "hold" rating for the company. Eleven investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $106.23.
Read Our Latest Research Report on ITCI
About Intra-Cellular Therapies
(
Free Report)
Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.
Recommended Stories
Before you consider Intra-Cellular Therapies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Intra-Cellular Therapies wasn't on the list.
While Intra-Cellular Therapies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
